Interpretation of the Major Updates of Guidelines Regarding Hyperuricemia and Gout in Chronic Kidney Disease

doi:10.12114/j.issn.1007-9572.2021.00.573

Abstract

Abstract: The incidence of hyperuricemia（HUA）and gout is increasing significantly，and tends to occur at an early age with the social development and changes in patterns of life. HUA has become the second leading metabolic disease following diabetes mellitus，which is not only a common complication of chronic kidney disease（CKD），but also an important risk factor for CKD. The guidelines for the diagnosis and treatment of HUA and gout have been updated to accommodate newly emerging evidence. We interpreted the essentials of new updates regarding HUA and gout in CKD on the basis of research evidence，including the indication of initial urate-lowering therapy，selection of pharmacologic urate-lowering therapy，gout flare management，alkalinizing urine and use of vitamin C on the basis of research evidence，hoping to provide clinicians with supports for delivering comprehensive and individual therapies.

Key words: Kidney diseases, Hyperuricemia, Gout, Guidebook, Therapy

摘要： 随着社会发展及人们生活方式的改变，高尿酸血症（HUA）与痛风的发病率显著上升，并有年轻化趋势。目前HUA已成为仅次于糖尿病的第二大代谢性疾病，其不仅是慢性肾脏病（CKD）的常见并发症，而且是导致CKD发生和发展的重要原因。基于新的研究证据，国内外有关HUA与痛风诊治指南不断更新，并提出较多新观点。本文主要从CKD角度对国内外有关HUA与痛风的指南更新要点进行解读，并结合相关研究证据从初始降尿酸治疗指征、降尿酸治疗药物的选择、痛风急性发作的管理、碱化尿液、维生素C的使用方面进行分析和探讨，旨在为临床综合性、个体化治疗提供借鉴和帮助。

关键词: 肾疾病, 高尿酸血症, 痛风, 指南, 治疗

WANG Xu,LUO Dongping,RU Yanhai, et al. Interpretation of the Major Updates of Guidelines Regarding Hyperuricemia and Gout in Chronic Kidney Disease　[J]. Chinese General Practice, 2021, 24(33): 4191-4195. DOI: 10.12114/j.issn.1007-9572.2021.00.573.
王旭,罗冬平,茹彦海等. 从慢性肾脏病角度看高尿酸血症与痛风的指南更新要点[J]. 中国全科医学, 2021, 24(33): 4191-4195. DOI: 10.12114/j.issn.1007-9572.2021.00.573.

References

［1］易凤，姜俊，兰雷，等．IgA肾病患者高尿酸血症的相关因素分析［J］．中华肾脏病杂志，2019，35（11）：816-821．DOI：10.3760/cma.j.issn.1001-7097.2019.11.003.
YI F，JIANG J，LAN L，et al．Related factors of hyperuricemia in IgA nephropathy patients［J］．Chin J Nephrol，2019，35（11）：816-821．DOI：10.3760/cma.j.issn.1001-7097.2019.11.003.
［2］CHANG Y H，LEI C C，LIN K C，et al．Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus——a 4.6-year cohort study［J］．Diabetes Metab Res Rev，2016，32（6）：557-564．DOI：10.1002/dmrr.2768.
［3］ZUO T，JIANG L，MAO S，et al．Hyperuricemia and contrast-induced acute kidney injury：a systematic review and meta-analysis［J］．Int J Cardiol，2016，224：286-294．DOI：10.1016/j.ijcard.2016.09.033.
［4］FITZGERALD J D，DALBETH N，MIKULS T，et al．2020 American College of Rheumatology guideline for the management of gout［J］．Arthritis Care Res（Hoboken），2020，72（6）：744-760．DOI：10.1002/acr.24180.
［5］中华医学会内分泌学分会.中国高尿酸血症与痛风诊疗指南（2019）［J］．中华内分泌代谢杂志，2020，36（1）：1-13．DOI：10.3760/cma.j.issn.1000-6699.2020.01.001.
Chinese Society of Endocrinology，Chinese Medical Association.Guideline for the diagnosis and management of hyperuricemia and gout in China（2019）［J］．Chin J Endocrinol Metab，2020，36（1）：1-13．DOI：10.3760/cma.j.issn.1000-6699.2020.01.001.
［6］高尿酸血症相关疾病诊疗多学科共识专家组.中国高尿酸血症相关疾病诊疗多学科专家共识［J］．中华内科杂志，2017，56（3）：235-248．DOI：10.3760/cma.j.issn.0578-1426.2017.03.021.
Multi-Disciplinary Expert Task Force on Hyperuricemia and Its Related Diseases.Chinese multi-disciplinary consensus on the diagnosis and treatment of hyperuricemia and its related diseases［J］．Chin J Intern Med，2017，56（3）：235-248．DOI：10.3760/cma.j.issn.0578-1426.2017.03.021.
［7］NAKAYA I，NAMIKOSHI T，TSURUTA Y，et al．Management of asymptomatic hyperuricaemia in patients with chronic kidney disease by Japanese nephrologists：a questionnaire survey［J］．Nephrology（Carlton），2011，16（5）：518-521．DOI：10.1111/j.1440-1797.2011.01446.x.
［8］CHA R H，KIM S H，BAE E H，et al．Physicians' perceptions of asymptomatic hyperuricemia in patients with chronic kidney disease：a questionnaire survey［J］．Kidney Res Clin Pract，2019，38（3）：373-381．DOI：10.23876/j.krcp.19.007.
［9］KIMURA K，HOSOYA T，UCHIDA S，et al．Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia：a randomized trial［J］．Am J Kidney Dis，2018，72（6）：798-810．DOI：10.1053/j.ajkd.2018.06.028.
［10］王惠芳，张伟，李宁，等．非布司他治疗慢性肾脏病3~5期伴高尿酸血症患者的疗效分析及对肾功能的影响［J］．中华肾脏病杂志，2017，33（10）：721-728．DOI：10.3760/cma.j.issn.1001-7097.2017.10.001.
WANG H F，ZHANG W，LI N，et al．The urate- lowering efficacy of febuxostat and its effect on renal function in hyperuricemic patients with chronic kidney disease stages 3-5［J］．Chinese Journal of Nephrology，2017，33（10）：721-728．DOI：10.3760/cma.j.issn.1001-7097.2017.10.001.
［11］GONZALEZ-GALARZA F F，TAKESHITA L Y，SANTOS E J，et al．Allele frequency net 2015 update：new features for HLA epitopes，KIR and disease and HLA adverse drug reaction associations［J］．Nucleic Acids Res，2015，43（Database issue）：D784-788．DOI：10.1093/nar/gku1166.
［12］WHITE W B，SAAG K G，BECKER M A，et al．Cardiovascular safety of febuxostat or allopurinol in patients with gout［J］．N Engl J Med，2018，378（13）：1200-1210．DOI：10.1056/nejmoa1710895.
［13］UCHIDA S，SHIMADA K，MISAKA S，et al．Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes［J］．Drug Metab Pharmacokinet，2010，25（6）：605-610．DOI：10.2133/dmpk.dmpk-10-nt-040.
［14］STAMP L K，TAYLOR W J，JONES P B，et al．Starting dose is a risk factor for allopurinol hypersensitivity syndrome：a proposed safe starting dose of allopurinol［J］．Arthritis Rheum，2012，64（8）：2529-2536．DOI：10.1002/art.34488.
［15］PAISANSINSUP T，BREITENSTEIN M K，SCHOUSBOE J T.Association between adverse reactions to allopurinol and exposures to high maintenance doses：implications for management of patients using allopurinol［J］．J Clin Rheumatol，2013，19（4）：180-186．DOI：10.1097/RHU.0b013e31829372e6.
［16］TSURUTA Y，NITTA K，AKIZAWA T，et al．Association between allopurinol and mortality among Japanese hemodialysis patients：results from the DOPPS［J］．Int Urol Nephrol，2014，46（9）：1833-1841．DOI：10.1007/s11255-014-0731-0.
［17］BECKER M A，SCHUMACHER H R，ESPINOZA L R，et al．The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout：the CONFIRMS trial［J］．Arthritis Res Ther，2010，12（2）：R63．DOI：10.1186/ar2978.
［18］CHEN C H，CHEN C B，CHANG C J，et al．Hypersensitivity and cardiovascular risks related to allopurinol and febuxostat therapy in asians：a population-based cohort study and meta-analysis［J］．Clin Pharmacol Ther，2019，106（2）：391-401．DOI：10.1002/cpt.1377.
［19］中国慢性肾脏病患者合并高尿酸血症诊治共识专家组.中国慢性肾脏病患者合并高尿酸血症诊治专家共识［J］．中华肾脏病杂志，2017，33（6）：463-469．DOI：10.3760/cma.j.issn.1001-7097.2017.06.012.
［20］陆世凯.不同剂量秋水仙碱治疗痛风性关节炎患者的临床效果比较［J］．中华全科医学，2017，15（10）：1700-1703．DOI：10.16766/j.cnki.issn.1674-4152.2017.10.019.
LU S K.Clinical effect of the different dosage of colchicine on 98 cases of gouty arthritis［J］．Chinese Journal of General Practice，2017，15（10）：1700-1703．DOI：10.16766/j.cnki.issn.1674-4152.2017.10.019.
［21］STAMP L K，O'DONNELL J L，FRAMPTON C，et al．Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout：a pilot randomized controlled trial［J］．Arthritis Rheum，2013，65（6）：1636-1642．DOI：10.1002/art.37925.
［22］FERRARO P M，CURHAN G C，GAMBARO G，et al．Total，dietary，and supplemental vitamin C intake and risk of incident kidney stones［J］．Am J Kidney Dis，2016，67（3）：400-407．DOI：10.1053/j.ajkd.2015.09.005.
［23］BINIAZ V，TAYEBI A，EBADI A，et al．Effect of vitamin C supplementation on serum uric acid in patients undergoing hemodialysis：a randomized controlled trial［J］．Iran J Kidney Dis，2014，8（5）：401-407.
［24］吴书涛，陆奎英，张敏，等．维生素C对3种不同厂家试剂血尿酸检测结果的影响［J］．国际检验医学杂志，2017，38（8）：1106-1107．DOI：10.3969/j.issn.1673-4130.2017.08.038.
［25］TAYLOR T H，MECCHELLA J N，LARSON R J，et al．Initiation of allopurinol at first medical contact for acute attacks of gout：a randomized clinical trial［J］．Am J Med，2012，125（11）：1126-1134.e7．DOI：10.1016/j.amjmed.2012.05.025.

[1]	ZHOU Penglong, CHANG Jing, DING Suying, CHEN Jingfeng, WANG Tao, LI Chenyang. Correlation Analysis between Age-Stratified Differences in Fat-to-muscle Ratio and Hyperuricemia [J]. Chinese General Practice, 2025, 28(27): 3375-3384.
[2]	CHEN Dian, LONG Huanyu, ZHANG Congxi, CHU Lanhe, LI Shurun, CHEN Yahong. Interpretation of Global Strategy for the Diagnosis, Treatment, Management and Prevention of Chronic Obstructive Pulmonary Disease 2025 Report [J]. Chinese General Practice, 2025, 28(16): 1937-1949.
[3]	WANG Yiquan, CHEN Wanjia, LIU Wangyi, ZHANG Luyun, DENG Yueyi. The Prognosis of Stage 4 Chronic Kidney Diseasetreated with Fermented Cordyceps Sinensis Powder: Based on a Retrospective Cohort Study [J]. Chinese General Practice, 2025, 28(09): 1084-1091.
[4]	Chinese Association of Geriatric Sleep Medicine, Chinese Geriatrics Society. Chinese Consensus on Application Speifications for Noninvasive Positive Pressure Ventilation of Elderly Patients with Obstructive Sleep Apnea [J]. Chinese General Practice, 2024, 27(31): 3841-3849.
[5]	QI Haiyan, WANG Jie, LUO Yuxi, WU Yun. Correlation Study between Hyperuricemia and Chronic Pulmonary Heart Disease: Based on LASSO Regression and Propensity Score Matching [J]. Chinese General Practice, 2024, 27(24): 2954-2960.
[6]	HUANG Shuwei, ZHOU Zhiheng, FENG Tianyuan, LIU Li, DENG Guangpu, LI Yaotian, ZHU Hong. Study on the Predictive Value of Different Insulin Resistance Replacement Indices for Hyperuricemia in Middle-aged and Elderly Patients with Type 2 Diabetes [J]. Chinese General Practice, 2024, 27(19): 2364-2374.
[7]	CHEN Dian, LONG Huanyu, LI Shurun, CHEN Yahong. Interpretation of Global Strategy for the Diagnosis, Treatment, Management and Prevention of Chronic Obstructive Pulmonary Disease 2024 Report [J]. Chinese General Practice, 2024, 27(13): 1533-1543.
[8]	SHI Weili, LI Mingyan, DUAN Hongyan. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Interpretation of the U.S. Preventive Services Task Force Recommendation Statement [J]. Chinese General Practice, 2024, 27(12): 1405-1412.
[9]	LI Mingyan, SHI Weili, DUAN Hongyan. Aspirin Use to Prevent Cardiovascular Disease in Adults: Interpretation of U.S. Preventive Services Task Force Recommendations Statement [J]. Chinese General Practice, 2024, 27(11): 1277-1282.
[10]	LI Yingchen, ZHAO Mingfang, WU Ying. Current Status of Lung Cancer Screening and Interpretation of the U.S. Preventive Services Task Force Guidelines on Lung Cancer Screening [J]. Chinese General Practice, 2024, 27(11): 1283-1287.
[11]	LI Xing, YANG Yining. Prevalence of Hyperuricemia and Its Correlation with Cardiometabolic Index in Xinjiang Region [J]. Chinese General Practice, 2024, 27(09): 1095-1101.
[12]	Quality Assessment Group for Quantitative Research, Systematic Review and Guidelines/Consensus of Chinese General Practice. Report on Methodological Quality Assessment of Primary Care and General Practice Research in China in 2021: Quantitative Research, Systematic Review and Guidelines/Consensus Section [J]. Chinese General Practice, 2024, 27(07): 773-783.
[13]	Psychosomatic Medicine Society of the Chinese Medical Association, Cardiovascular Disease Prevention and Rehabilitation Committee of Chinese Association of Rehabilitation Medicine, DING Rongjing, LIU Yuanyuan, YUAN Lixia, WANG Yibo, LI Zhongyan. Chinese Expert Consensus on the Construction Standardization of Psycho-cardiology Outpatient [J]. Chinese General Practice, 2024, 27(03): 253-261.
[14]	FANG Jiawen, FENG Tianyuan, ZHOU Zhiheng, LI Ziyue, YAN Danhong, LIN Kaicheng. Trend Analysis of Gout Burden in China from 1990 to 2019 and Prediction for the Next Ten Years [J]. Chinese General Practice, 2024, 27(02): 245-252.
[15]	Holistic Health Coordination Group of the Psychosomatic Medicine Society of the Chinese Medical Association. Chinese Expert Consensus on Diagnosis and Treatment of Psychiatric Dizziness [J]. Chinese General Practice, 2024, 27(02): 125-131.